Radiation Oncology
Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.
Recent Discussions
Is whole body phototherapy for skin disorders a contraindication to chest wall or breast radiation?
I would not consider prior phototherapy a contraindication. I regularly treat patients with cutaneous lymphomas and occasionally, refractory dermatitis after phototherapy, mostly narrow band UVB. Some of them have received maintenance phototherapy for 1-2 years before treatment with significant skin...
Is a larger prostate size or volume associated with a higher absolute PSA bounce after radiation?
I have not seen anything in the literature to indicate that the magnitude of the PSA bounce is related to prostate size, but it's certainly possible. The highest bounces I have seen after treatment were in patients treated with LDR brachytherapy (my personal record is 8 ng/mL, and it eventually beca...
How do you treat adrenal metastases with SBRT?
Adrenal glands move quite a bit with breathing. I would strongly recommend some form of motion management, either with breath hold, or 4DCT with abdominal compression, (the latter of which is my personal preference). I draw GTV (just tumor, not entire adrenal gland) as defined on whatever imaging sh...
What is the best SBRT dose-fractionation scheme for oligometastatic disease in the adrenal gland?
I don't think we have established a true "best" SBRT dose-fractionation schedule for any anatomical site, even the common ones where we have randomized trials comparing different dose regimens (ie lung), as the volume of data provides successful and acceptable alternatives but not necessarily a defi...
Does the presence of LCIS on pathology in a patient with IDC impact your decision to offer APBI?
It doesn’t change the decisions for APBI with all other factors being favorable. We offer APBI to invasive lobular also if it meets all criteria and had MRI breast done as part of the evaluation.
How do you approach adjuvant therapy for resected lung adenocarcinoma that was found unexpectedly postop to be N2?
Preliminary results of the phase 3 randomized LungART trial (NCT00410683) were recently presented at a virtual ESMO conference. 501 patients with pathologically confirmed N2 NSCLC s/p complete resection were randomized to postoperative RT (54 Gy) or observation. Almost all patients received chemothe...
How would you manage a solitary, painful, lytic bony lesion in a patient with negative PET/CT but bone marrow biopsy confirmation of multiple myeloma?
This is a palliative scenario, but the approach may differ based on the clinical circumstances. If Heme Onc is planning on administering systemic therapy, then a short course of palliative RT to expedite pain control would be appropriate. Treatment of many sites (e.g., femur) can be done very quickl...
What, if any, radiation regimen would you use for knee arthrofibrosis in a patient undergoing repeat arthroscopy with lysis of adhesions?
The high-dose single fraction regimens seem to be adapted from heterotopic ossification protocols and would be my choice if there was a concern for HO. If the concern is for the reaccumulation of fibrotic tissue, I favor LDRT such as 0.5 Gy 2-3 doses weekly for 6-8 fractions. There will be more sust...
Do you typically recommend avoiding neupogen during radiation treatments?
It depends on the reason and expected benefit. If myelosuppression is holding up RT for cervical cancer patients, then I would not hesitate to give neupogen to avoid or minimize a treatment break. There would be more benefit to neupogen and continuing RT than a downside. Usually, I would try to give...
How do you approach cisplatin dosing for locally advanced head and neck SCC in HPV-positive and HPV-negative patients?
Weekly cisplatin 40 mg/m² is not yet considered equivalent to high-dose cisplatin 100 mg/m² every three weeks, and high-dose cisplatin remains the preferred regimen for both HPV-positive and HPV-negative locally advanced head and neck squamous cell carcinoma. However, weekly cisplatin is an acceptab...